New York translation
Roche's new translational center will let pRED conduct early POC studies
Now headquartered at the newly opened Translational Clinical Research Center in New York, Roche's Pharma Research & Early Development organization has undergone another retooling intended to increase its efficiency and productivity. The center will enable pRED to access local expertise and patient populations for early human proof-of-concept studies.
On Oct. 1, Roche inaugurated the 250-person Translational Clinical Research Center (TCRC), which will serve as the headquarters for the pharma's clinical operations in the U.S., according to John Reed, the new head of pRED.
While he does not plan to undertake a major restructuring, late last month Reed implemented changes that included reorganizing pRED's four discovery and translational areas (DTAs) into three: oncology, infectious diseases and CNS/ophthalmology/rare diseases.
Reed also re-merged large and small molecule research into a single therapeutic modality function.
He also created the Academic Relations and Collaborations (ARC) taskforce, which will be headquartered at TCRC and manage the pharma's outreach to academic researchers, small companies and clinicians worldwide.
Reed also is interim head of the oncology DTA and a member of Roche's corporate executive committee.
In January, he stepped down as head of Sanford-Burnham Medical Research Institute, where he is still an adjunct professor at the institute's NCI-designated cancer center.
Ringing the changes
According to Reed, the reshuffling of pRED resulted from his seven-month evaluation of its pipeline.
Roche launched pRED in 2010 as one of its autonomous research centers, alongside Genentech Research & Early Development (gRED) at its Genentech Inc. unit. Each group is given an annual budget and a target for the